The stock of Great Basin Scientific Inc (NASDAQ:GBSN) is a huge mover today! The stock decreased 3.38% or $0.08 during the last trading session, hitting $2.29. About 174,543 shares traded hands. Great Basin Scientific Inc (NASDAQ:GBSN) has declined 86.04% since February 29, 2016 and is downtrending. It has underperformed by 96.46% the S&P500.
The move comes after 6 months negative chart setup for the $1.84 million company. It was reported on Oct, 1 by Barchart.com. We have $2.04 PT which if reached, will make NASDAQ:GBSN worth $202,400 less.
Analysts await Great Basin Scientific Inc (NASDAQ:GBSN) to report earnings on November, 21.
According to Zacks Investment Research, “Great Basin Scientific, Inc. is a molecular diagnostics company. It is focused on improving patient care through the development and commercialization of its patented, molecular diagnostic platform designed to test for infectious disease, especially hospital-acquired infections. Great Basin Scientific, Inc. is headquartered in Salt Lake City, Utah.”
More important recent Great Basin Scientific Inc (NASDAQ:GBSN) news were published by: Streetinsider.com which released: “Great Basin Scientific (GBSN) Launches Staph ID/R BCP Commercially in U.S., Europe” on September 20, 2016, also Finance.Yahoo.com published article titled: “Great Basin Scientific Receives Delisting Warning from Nasdaq”, Seekingalpha.com published: “Great Basin Scientific, Inc. – How Long Will It Survive?” on September 14, 2016. More interesting news about Great Basin Scientific Inc (NASDAQ:GBSN) was released by: Businesswire.com and their article: “Great Basin Scientific Announces Annual Meeting Results” with publication date: September 12, 2016.
GBSN Company Profile
Great Basin Scientific, Inc., incorporated on August 12, 2008, is a molecular diagnostic testing company. The Firm is focused on the development and commercialization of its molecular diagnostic platform designed to test for infectious diseases, especially hospital-acquired infections. The Firm has commercially available tests for clostridium difficile (C. diff) and Group B Strep. The Company’s system includes an analyzer and a diagnostic cartridge. Each analyzer contains a module into, which individual test cartridges are placed. The Company’s other diagnostic assays in the late stages of product development include a pre-surgical nasal screen for Staphylococcus aureus (SA), food borne pathogen panel, panel for candida blood infections, test for pertussis and a test for Chlamydia tracomatis (CT)/Neisseria gonorrhea (NG). It also has a pipeline of assays in an early stage of development, including respiratory testing and sepsis (blood infection) panels. The Firm markets a platform of molecular testing in small to medium sized hospitals.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.